Melanoma Clinical Trials

Showing 581-600 of 1,477 trials

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

NCT04899921

The purpose of this research is to test the safety and effectiveness of the investigational combination of Troriluzole, ipilimumab, and nivolumab, and to learn whether this combination works in treating melanoma that has spread to the brain.

MelanomaMetastatic Melanoma

Dana-Farber Cancer Institute1 participantsStarted Jun 2021

Boston, Massachusetts, United States • Boston, Massachusetts, United States

COMPLETEDPhase 1

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

NCT03590054

This phase I trial studies the best dose and side effects of abexinostat and how well it works with given together with pembrolizumab in treating participants with microsatellite instability (MSI) solid tumors that have spread to other places in the body. Abexinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving abexinostat and pembrolizumab may work better in treating participants with solid tumors.

Stage III Cutaneous MelanomaStage IV Cutaneous MelanomaLocally Advanced Melanoma+18 more

Rahul Aggarwal35 participantsStarted Aug 2018

San Francisco, California, United States

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

Related Searches

Ipilimumab and Imatinib Mesylate in Advanced Cancer

Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma

Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.

DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

Nevus Doctor Clinical Decision Support for GPs

Longitudinal Follow-Up of Patients Treated With Hypofractionated Stereotactic Photon Radiotherapy Due to Uveal Melanoma

Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic Surgery

Shared Decision Making in Melanoma Patients Receiving Adjuvant Therapy

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma

Characteristics and Tumor Staging Proposal for Primary Malignant Melanoma of the Esophagus

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

Uveal Melanoma - Comparative Study

Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1